Publications (71)

2021

  1. The role of the pharmacist within an immune-mediated inflammatory disease unit: Results of a survey of healthcare providers and patients

    Farmacia Hospitalaria, Vol. 45, Núm. 6, pp. 305-316

  2. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 893-899

  3. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients beyond the Indication of Clinical Trials: 48 Weeks' Results

    AIDS Research and Human Retroviruses, Vol. 37, Núm. 10, pp. 761-767

  4. Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study

    Pulmonary Pharmacology and Therapeutics, Vol. 69

  5. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

    Reumatologia Clinica, Vol. 17, Núm. 6, pp. 335-342

2019

  1. Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 43, Núm. 1, pp. 24-30

  2. Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 367-372

2018

  1. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price

    International Journal of Clinical Pharmacy, Vol. 40, Núm. 6, pp. 1528-1538

2011

  1. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Núm. 4, pp. 457-477

  2. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

  3. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

    The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283

2010

  1. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 8, pp. 1567-1569

  2. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

  3. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  4. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  5. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

    Journal of Infectious Diseases, Vol. 202, Núm. 8, pp. 1185-1191

  6. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547

2009

  1. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

  2. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

  3. Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities

    Drug Metabolism Letters, Vol. 3, Núm. 2, pp. 67-69